Dare Bioscience, Inc. Net Fee Amt
Dare Bioscience, Inc. (DARE) had Net Fee Amt of $1.01 thousand as of 2026-08-26, per its S-1 filed 2026-08-26.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-26
- 2026-08-26: Net Fee Amt $1.01K.
- 2026-06-23: Net Fee Amt $426.73.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-26 | $1.01K S-1 · filed 2026-08-26 |
| 2026-06-23 | $426.73 S-8 · filed 2026-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |